LUBRIGONE SIGNED

Project "LUBRIGONE" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

With a global value of €4,663 million in 2017, Prefillable syringes (PFS) for administration of medical injections have seen an increased use in recent years, thanks to their advantages over the combined use of empty syringes and vials, such as their ease of use, accurate dosage (with less overfill), improved safety and reduced risk of contamination However, PFS require lubrication (usually liquid or baked-on silicone) to ensure their functionality, and this lubrication (which is in direct contact with the medical dosage in the PFS throughout its entire shelf life) may affect the pharmaceutical compounds, reducing their efficacy and causing health and safety issues for patients. To solve this problem, we developed LUBRIGONE, a new line of PFS stoppers combining a chemically inert Thermoplastic Elastomer (TPE) and unique sealing profile designs, which eliminates the need for lubrication and/or coating of the stopper and container. In this way, LUBRIGONE enables a completely clean injection system, protecting sensitive injectables from pollution, and protecting users against potential damage, while granting an optimal functionality (maintaining an acceptable break loose force and mean forces in PFS). Our company, Injecto A/S was founded in 2014 with the goal to develop safe medical devices with primary focus on safe PFS syringes and their stoppers, to create safe and long-term stable drug injections. As a result, the LUBRIGONE project, will be a cornerstone for us, as it will enable us to exploit the market opportunity derived from its competitive advantages over current silicone-oil coated rubber stoppers, and the lack of feasible cost-effective alternatives, In this way, it will facilitate our growth and international expansion: our forecasts are to sell 21.4 million units in the first 4 years of commercialization, resulting in €10.7 million accumulated revenues by 2024, and increasing our staff by 250%